Effect of Coronary Percutaneous Revascularization on Interferon-γ and Interleukin-10 Producing CD4+ T Cells during Acute Myocardial Infarction
暂无分享,去创建一个
F. Fedele | D. Accapezzato | M. Mancone | G. Sardella | L. De Luca | F. Fedele | V. Francavilla | A. Di Roma | M. Paroli | R. Colantonio | O. Gianoglio | A. D. Roma | L. D. Luca
[1] T. Lagerweij,et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. , 2007, Atherosclerosis.
[2] F. Fedele,et al. Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. , 2007, Thrombosis research.
[3] G. Keren,et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. , 2006, European heart journal.
[4] J. Tijssen,et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.
[5] B. Nakken,et al. Th1/Th2 Imbalance, Measured by Circulating and Intracytoplasmic Inflammatory Cytokines – Immunological Alterations in Acute Coronary Syndrome and Stable Coronary Artery Disease , 2006, Scandinavian journal of immunology.
[6] K. Hatakeyama,et al. Increased expression of interleukin-10 in unstable plaque obtained by directional coronary atherectomy. , 2006, European heart journal.
[7] A. Kirtane,et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. , 2006, The American journal of cardiology.
[8] T. Kılıç,et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome , 2006, Heart.
[9] R. Flavell,et al. Natural regulatory T cells control the development of atherosclerosis in mice , 2006, Nature Medicine.
[10] G. Keren,et al. Altered status of CD 4 1 CD 25 1 regulatory T cells in patients with acute coronary syndromes , 2006 .
[11] Ildikó Kriszbacher,et al. Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.
[12] E. Edelman,et al. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. , 2005, Journal of the American College of Cardiology.
[13] F. Alfonso,et al. Fatal infection after rapamycin eluting coronary stent implantation , 2005, Heart.
[14] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[15] F. Fedele,et al. Integrin β2-Chain (CD18) Over-Expression on CD4+ T Cells and Monocytes after Ischemia/Reperfusion in Patients Undergoing Primary Percutaneous Revascularization , 2004, International journal of immunopathology and pharmacology.
[16] E. Bruera,et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. , 2004, Cytokine.
[17] M. Battaglia,et al. The role of interleukin 10 in the control of autoimmunity. , 2003, Journal of autoimmunity.
[18] M. D’Elios,et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. Heeschen,et al. Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes , 2003, Circulation.
[20] J. Boura,et al. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .
[21] G. Hansson,et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. , 2002, The Journal of clinical investigation.
[22] J. Kaski,et al. Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina , 2001, Circulation.
[23] R. de Waal Malefyt,et al. IFN-α and IL-10 Induce the Differentiation of Human Type 1 T Regulatory Cells1 , 2001, The Journal of Immunology.
[24] M. Zembala,et al. Three-Color Flow Cytometry Detection of Intracellular Cytokines in Peripheral Blood Mononuclear Cells: Comparative Analysis of Phorbol Myristate Acetate-Ionomycin and Phytohemagglutinin Stimulation , 2001, Clinical Diagnostic Laboratory Immunology.
[25] A. Maseri,et al. Evidence for Antigen-Driven T-Cell Response in Unstable Angina , 2000, Circulation.
[26] R. Frye,et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. , 2000, Circulation.
[27] M. Territo,et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[28] M. Bureau,et al. Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.
[29] A Daugherty,et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. , 1997, The Journal of clinical investigation.
[30] J. D. de Vries,et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells , 1996, The Journal of experimental medicine.
[31] A. Becker,et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.
[32] G. Hansson,et al. Immune mechanisms in atherosclerosis. , 1989, Arteriosclerosis.